Investigation of Novel Urinary Biomarkers in Hepatocellular Carcinoma Risk in a Predominantly African American Population: A Case-Control Study

Overview

Journal Gastrointest Tumors

Date 2024 Apr 9

PMID 38590513

Authors

Alexandra Shingina

Xijing Han

Lei Fan

Harvey Murff

Robert Coffey

Ginger L Milne

Qi Dai

Martha Shrubsole

Affiliations

Soon will be listed here.

Abstract

Introduction: African Americans are at increased risk of hepatocellular carcinoma (HCC) compared to other racial and ethnic groups. We investigated the associations of four urinary biomarkers of prostaglandin E (PGE-M), prostacyclin (PGI-M), and thromboxane (11dTxB) synthesis and the ratio of PGI-M to 11dTXB with HCC risk in a cohort of predominantly African American populations.

Methods: We conducted a nested case-control study (50 cases; 43 with HCC, 151 controls) in the Southern Community Cohort Study (SCCS), a large prospective cohort study including over 80,000 study participants, of whom two-thirds are African Americans. Urine samples were collected at enrollment and subsequently analyzed to assess biomarker levels. Multivariable regression models adjusted for age, race, sex, BMI, smoking status, NSAID use, education level, income, and alcohol consumption were used to assess the relationship between the biomarker and HCC risk.

Results: Only 11dTxB (OR = 11.50; 95% CI [2.34-56.47] for highest tertile vs. lowest tertile, = 0.004) and the PGI-M/11dTXB ratio of the second quartile (0.25-0.49) (OR = 5.16; 95% CI [1.44-18.47]; = 0.01) were significantly associated with increased risk of liver cancer.

Conclusion: 11dTXB and PGI-M/11dTXB ratio may be urinary markers of HCC risk, particularly among African Americans, and future prospective studies are needed to evaluate this finding further and to develop accessible methods.

References

Ferroni P, Santilli F, Cavaliere F, Simeone P, Costarelli L, Liani R . Oxidant stress as a major determinant of platelet activation in invasive breast cancer. Int J Cancer. 2016; 140(3):696-704. DOI: 10.1002/ijc.30488. View

Ashktorab H, Kupfer S, Brim H, Carethers J . Racial Disparity in Gastrointestinal Cancer Risk. Gastroenterology. 2017; 153(4):910-923. PMC: 5623134. DOI: 10.1053/j.gastro.2017.08.018. View

Jara-Gutierrez A, Baladron V . The Role of Prostaglandins in Different Types of Cancer. Cells. 2021; 10(6). PMC: 8231512. DOI: 10.3390/cells10061487. View

Gomes R, Felipe da Costa S, Colquhoun A . Eicosanoids and cancer. Clinics (Sao Paulo). 2018; 73(suppl 1):e530s. PMC: 6096979. DOI: 10.6061/clinics/2018/e530s. View

Lai Y, Liu H, Chiang W, Chen T, Chu L, Yu J . MiR-31-5p-ACOX1 Axis Enhances Tumorigenic Fitness in Oral Squamous Cell Carcinoma Via the Promigratory Prostaglandin E2. Theranostics. 2018; 8(2):486-504. PMC: 5743562. DOI: 10.7150/thno.22059. View

Aitokallio-Tallberg A . Prostacyclin and thromboxane synthesis by endometrial cancer and leiomyomas. Prostaglandins. 1990; 39(3):259-66. DOI: 10.1016/0090-6980(90)90045-w. View

Momin B, Pinheiro P, Carreira H, Li C, Weir H . Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer. 2017; 123 Suppl 24:5059-5078. PMC: 5759038. DOI: 10.1002/cncr.30820. View

Altobelli E, Angeletti P, Latella G . Role of Urinary Biomarkers in the Diagnosis of Adenoma and Colorectal Cancer: A Systematic Review and Meta-Analysis. J Cancer. 2016; 7(14):1984-2004. PMC: 5118662. DOI: 10.7150/jca.16244. View

Kij A, Kus K, Smeda M, Zakrzewska A, Proniewski B, Matyjaszczyk K . Differential effects of nitric oxide deficiency on primary tumour growth, pulmonary metastasis and prostacyclin/thromboxane A balance in orthotopic and intravenous murine models of 4T1 breast cancer. J Physiol Pharmacol. 2019; 69(6). DOI: 10.26402/jpp.2018.6.05. View

10.

Zardi E, Gentilucci U, Picardi A, Ambrosino G, Fazio V, Dobrina A . Iloprost: an adjunctive approach to chronic viral hepatitis treatment. Med Hypotheses. 2004; 64(1):46-52. DOI: 10.1016/j.mehy.2004.05.017. View

11.

Moussa O, Yordy J, Abol-Enein H, Sinha D, Bissada N, Halushka P . Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Res. 2005; 65(24):11581-7. DOI: 10.1158/0008-5472.CAN-05-1622. View

12.

Johnson J, Schmidt C, Shrubsole M, Billheimer D, Joshi P, Morrow J . Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol. 2006; 4(11):1358-65. DOI: 10.1016/j.cgh.2006.07.015. View

13.

Drew D, Schuck M, Magicheva-Gupta M, Stewart K, Gilpin K, Miller P . Effect of Low-dose and Standard-dose Aspirin on PGE Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial. Cancer Prev Res (Phila). 2020; 13(10):877-888. PMC: 7541643. DOI: 10.1158/1940-6207.CAPR-20-0216. View

14.

Im J, Fu W, Wang H, Bhatia S, Hammer D, Kowalska M . Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 2004; 64(23):8613-9. DOI: 10.1158/0008-5472.CAN-04-2078. View

15.

Zang S, Ma X, Wu Y, Liu W, Cheng H, Li J . PGE synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma. Hum Pathol. 2017; 63:120-127. DOI: 10.1016/j.humpath.2017.02.018. View

16.

Yuan J, Grouls M, Carmella S, Wang R, Heskin A, Jiang Y . Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma. Carcinogenesis. 2019; 40(8):989-997. PMC: 7967701. DOI: 10.1093/carcin/bgy180. View

17.

Green K . Metabolism of prostaglandin E2 in the rat. Biochemistry. 1971; 10(6):1072-86. DOI: 10.1021/bi00782a022. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Montine T, Sonnen J, Milne G, Baker L, Breitner J . Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. PLoS One. 2010; 5(2):e9340. PMC: 2824826. DOI: 10.1371/journal.pone.0009340. View

20.

Yokoyama I, Hayashi S, Kobayashi T, Negita M, Yasutomi M, Uchida K . Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor. Res Exp Med (Berl). 1995; 195(4):209-15. DOI: 10.1007/BF02576790. View